Developing Integrated Health and Care





North East and North Cumbria


Working for people from North Yorkshire to the Scottish Borders

Digital strategy for the NENE ICS – Enabling the transformation of care ...through the use of digital technology

Dr Mark Dornan Digital Care Programme SRO








North East and North Cumbria STP/ICS Programmes

Delivery Programmes						
Optimising Acute Services (inc. Pathology, Radiology, Paediatrics etc)	Care Closer to Home (inc. Frail Elderly Framework)					
Urgent & Emergency Care	Cancer					
Mental Health	Learning Disabilities					
Prevention	Continuing Health Care					
Enabling Program	mmes/Strategies					
Workforce	System Development					
Digital Care	Demand Management					
Estates	Communications & Engagement					
Transport						

North East and North Cumbria Digital Governance Structure



Attendees of Digital Strategy Group:

SRO Digital Care Programme GNCR lead CCIO CCIO network representative (FT) CCIO network representative (CCG) CIO Network chair CIO Primary Care (on behalf of) Digital Care Finance lead Cumbria ICP Durham and Tees Valley ICP Northern ICP Central ICP

AHSN/Academic link Local Authority senior rep SIGN group rep NHS England/Improvement NHS Digital Patients and Public rep Regional Health watch rep Director of Clinical Networks Programme Manager

Others invited as per agenda

North East and North Cumbria Digital Care - Strategic alignment

Current Drojecto	Themes (we what we are	Mision
Current Projects	Themes/ workstreams	Vision
HSCN Implementation - health and local government collaboration	Robust, secure and appropriate Infrastructure	
Cyber Security (prevention)		
Wi-Fi - a) Trusts b) Primary care		
EPR		
Scan for Safety (S4S)		
Digitising Community Pharmacy and Medicines	Mature Digital Providers and associated services	
Transfers of Care	Ŭ	
Pathology: integrated LIMS system/common IT platform and implementation of a new digital imaging solution (PACS)		
Great North Care Record (GNCR)		To enable the
GP Connect (National solution for limited record sharing)		delivery of high
Transforming Radiology using appropriate technology	Interoperable and Collaborative systems and resources	quality, efficient
Development of maternity digital personal health records (ePHRs)		health and care services, to the
Opportunities for collaboration ie. back office functions		Patients of the
E-consultation and video conferencing (tele medicine)		North East and
Technology Enabled Care Services (TECS/ telecare; HealthCall)	Digital innovations to deliver self-sufficient care delivered closer to	North Cumbria through digital
Primary Care Online Patient Access: Increased Utilisation (GPIT/national programme)	home in neighbourhoods and communities Enabling Care closer to home	solutions
Primary Care Maturity: Mobile Working in Primary care		
Current Analytics - Build further on the intelligence available via RAIDR, expanding from current access by all CCGs and GP practices, to include other organisation e.g. Foundation Trusts		
GNCR - Analytics - Improve future analytics capability across the region to support research and evaluation	Dynamic System Planning & Delivery underpinned through evidence, driven through data and analytical services	
e.g. Adopt the NHS Digital - Data Landing Portal for all flows of secondary use data between providers and commissioner		
NE&C Optimising the systems supporting Clinical Pathways		

Regional priority Share for learning and potential efficiencies

National programmes - delivered locally


I- CARE: Involve

Patients

- Patient online portal
- E-consultation

Staff

- Record access- MIG
- Communication




I- CARE: Consider

- Frailty screening tools
- SystmOne & EMIS integration SLIP programme
- RAIDR Population Health Management:
 - Using data from our existing systems & data flows
 - Risk stratification

Polypharmacy Review – STOPP as an example

Patient flag

Patient details – including what was decided last time reviewed



Page 1 Information			
Polypharmacy			
	IGI disease	CKD4/5	
			28
Previous polypharmacy issues	Notes	STOPP Alext Cral biophosphonaiss with a history of upper gastrointestinal disease i a dysphagia, oesophagits, gastritis, duodentis, or peptic ulcer disease, or upper gastrointestinal bioeding (risk for relapse/wascribation of oesophagits, oesophageal ulcer, oesophageal	
		stricture). Benefits of alendronate likely to outweigh risks	
	* 🚺 19 Feb 2016 Polyp	harmacy medication review (KaaCQ)	1
	Notes	STOPP Alert: Use of regular (as distinct from PRN) opioids without concomitant laxative (risk of severe constipation). No problems with constipation	
		No problems with consideration	
STOPP Protocol	STOPP Medication Re	view Summary (today's entries)	
To add comments: right click, choose Amendments-Amend Notee			

STOPP

Or reporting at a practice level – for systematic GP or pharmacist review

Bot (Dig NOT anial fibritation) NOT LVSD B02 Ditacem / Verapami AND heart failure B03 Beta blocker AND (Verapami OR diffusion) B04 beta blocker AND (Version Type 2 or complete heart block) B05 Amiodarone WITHOUT past or present B0 digouri veraeamil or diffusion B05 Compdiatione WITHOUT past present B0 digouri veraeamil or diffusion B05 Loop diaretic AND hypertension) WITHOUT (Heart failure, nephrotic syndrome OR CKD 4-5) B05 Thioted WITH (Sout or hypokalamil or hypercalizatiania or hypercalizaemia) B05 Centrality acting anthypertension WITH utinary incontinence B10 Centrality acting anthypertensives B11 ACE or ARB WITH K = 5.5 B12 Spiro diversion wITH K = sparing dirugs WITHOUT (+ in last 6 monthe B13 Phosphodiestareas inhibitors AND (Heart failure WITH Systolic < 90 OR Oral Nitrate) C01 Aspirin >160mg C02 Applinin AND peptic ulcer disease WITHOUTE	0 0.0 % 2 0.0 % 4 0.1 % 0 0.0 % 3 0.1 % 38 0.0 % 13 0.2 % 15 0.3 % 5 0.1 % 3 0.1 % 1 0.0 % 1 0.0 % 1 0.0 %	03 Sep 2018 16.50 (B), 03 Sep 2018 16.50 (B), 04 Sep 2018 16.50 (B), 05 Sep
B03 Beta blocker AND (verapamil OR diffuzzem) B04 beta blocker AND (verapamil OR diffuzzem) B05 Amoderne WTH-NOUT past or prevent B8 digion verapamil or diffuzzem B05 Amoderne WTH-NOUT past or prevent B8 digion verapamil or diffuzzem B05 (Loop diuretic AND hypertension) WTH-OUT (Heart failure or anthypertensive medication) B07 Loop diuretic WTH-B0UT theait failure, liver failure, nephrotic syndrome OR CHD 4-5) B09 Loop diuretic WTH-B0UT theait failure, internatiaemia or hypercalcaemia) B09 Loop diuretic WTH-H0UT theait failure, internatiaemia or hypercalcaemia) B09 Loop diuretic WTH-H0UT theait failure, internatiaemia or hypercalcaemia) B09 Loop diuretic WTH-H0UT theait failure, internationence B10 Centrally atting anthrpertension WTH-H0UT K+ in last 6 months B12 Spino or epierenous WTH-K * spaning diugs WTH-OUT K+ in last 6 months B13 Phosphodiseterase inhibitors AND (Heart failure WTH-Systolic <90 OR Grail Nitrate) C01 Aspinin >160mg C02 Aspinin AND peptic ulcer disease WiTH-OUT ppi	1 00% 4 01% 0 00% 3 01% 38 00% 13 02% 6 0.1% 3 01% 1 00% 1 00% 3 01%	03 Sep 2018 16 50 (a), 03 Sep 2018 16 50 (a),
B04 beta blocker AND (HR+30 Type 2 or complete heart block) B05 Amiodarone WTH+OUT past or present B0 digiouri vergaamil or dilitacem B06 (Loop diurstic AND type factsicing) WTH+OUT (Heart failure, nephrotic syndrome OR CKD 4-5) B07 Thiazide WTH+OUT (heart failure, liver failure, nephrotic syndrome OR CKD 4-5) B08 Thiazide WTH+ (Gout or hypotaliaamil or hyponatraemia or hypercalcaemia) B09 Loop diurstic WTH+DUT (heart failure, liver failure, nephrotic syndrome OR CKD 4-5) B09 Contrally acting anthippertensives B11 ACE or ARB WTH+K > 5.5 B12 Spiro or splice-mones WTH+K > 5.5 B13 Spiro or splice-mones WTH+K > 5.5 B13 Phosphodiesterase inhibitors AND (Heart failure WTH+Systolic <90 OR Oral Nitrate) C01 Aspinin AND peptic ulicer disease WTH+OUT ppi	4 0.1 % 0 0.0 % 38 0.0 % 13 0.2 % 15 0.3 % 6 0.1 % 3 0.1 % 1 0.0 % 3 0.1 % 0 0.0 %	03 84p 2018 16 50 (0), 03 84p 2018 16 50 (0),
B05 Amiodarone WITHOUT past or present BB digosin verapamil or diffacem B05 (Loop diuretic AND hypertension) WITHOUT (Heart failure or anthrpsentensive medication) B07 Loop diuretic WITHOUT (heart failure, nephrotic syndrome OR CKD 4-5) B09 Thistore WITH (Sout or hypertaliaemia or hypercaticaemia) B09 Thistore WITH (Sout or hypertaliaemia or hypercaticaemia) B09 Centrally acting anthrpertension WITH urinary incontinence B10 Centrally acting anthrpertensives B11 ACE or ARB WITH K + 5.5 B12 Spiro or epierentons WITH K + sparing drups WITHOUT K + in last 6 months B13 Phosphodiesterase inhibitors AND (Heart failure WITH Systolic <90 OR Grail Nitrate) C01 Aspirin AND peptic ulter disease WITHOUT ppi	0 0 0 % 3 01 % 30 00 % 13 0.2 % 15 0.3 % 6 0.1 % 3 01 % 1 0.0 % 1 0.0 %	03 Sep 2018 16.50 (0), 03 Sep
B06 (Loop diuretic AND hypertension) WITHOUT (Heart failure or anthypertensive medication) B07 Loop diuretic WITHOUT (heart failure, nephrotic syndrome OR CHD 4-5) B09 Thistofe WITH (South Hypertension anthypertainamia or hypercalcaemia) B09 Loop diuretic WITH hypertension WITH utinary incontinence B10 Centrally acting anthypertensives B11 ACE or ARB WITH K+ 5.5 B12 Spiro or epierentoes WITH K+ spaning diups WITHOUT K+ in last 6 months B13 Phosphodiesterase inhibitors AND (Heart failure WITH Systolic <90 OR Oral Nitrate) C01 Aspitin -160mg C02 Aspitin AND pepti ulter disease WITHOUTppi	3 0.1% 38 0.0% 13 0.2% 6 0.1% 3 0.1% 1 0.0% 1 0.0% 1 0.0% 1 0.0%	03 Bep 2018 16:50 (0), 03 Bep 2018 16:50 (0),
B87 Loop duratic WITHOUT (heart failure, liver failure, nephrotic syndrome OR CKD 4-5) B98 Thiaside WITH (Gout or hypokalaamia or hyponatraamia or hypercalcaemia) B99 Loop duratic WITH hypertension WITH urinary incontinence B10 Centrally acting antihypertensives B11 ACE or ARB WITH K* > 5.5 B12 Spito or splerences WITH K* sparing drugs WITHOUT K* in last 6 months B13 Phosphodiesterase inhibitors AND (Heart failure WITH Systotic <90 OR Grail Nitrate) C01 Aspitin =168mg C02 Aspitin AND peptic ulcer disease WITHOUT ppi	38 0.6 % 13 0.2 % 15 0.3 % 5 0.1 % 3 0.1 % 1 0.0 % 1 0.0 % 3 0.1 % 0 0.0 %	03 8ep 2018 16.50 (m), 03 8ep 2018 16.50 (m),
B09 Thiazide WITH (Gout or hypokalaemia or hyponatraemia or hypercalcaemia) B09 Loop diureds WITH hypertension WITH urinary incontinence B10 Centrally acting anthypertensives B11 ACE or ARB WITH K * 5.5 B12 Spiro or episrenone WITH K * sparing drugs WITHOUT K * in last 6 months B13 Phosphodiesterase inhibitors AND (Heart failure WITH Systolic <90 OR Oral Nitratol) C01 Aspirin AND peptic ulcer disease WITHOUT ppi	13 0.2 % 15 0.3 % 6 0.1 % 3 0.1 % 1 0.0 % 3 0.1 % 0 0.0 %	03 Bep 2010 16.50 (0), 03 Bep 2010 16.50 (0), 03 Bep 2018 16.50 (0), 03 Bep 2018 16.50 (0), 03 Bep 2018 16.50 (0), 03 Sep 2010 16.50 (0), 03 Sep 2010 16.50 (0), 03 Sep 2010 16.50 (0),
IB09 Loop duretic WITH hypertension WITH utiliary incontinence B10 Centrally acting antihypertensives B11 ACE or ARB WITH K* 5.5 B12 Spiro or epiecentons WITH K* sparing drups WITHOUT K* in last 8 months B13 Phosphodiesterase inhibitors AND (Heart failure WITH Systolic <90 OR Grai Nitrate) C01 Aspirin >160mg C02 Aspirin AND peptic ulcer disease WITHOUT ppi	15 03% 6 01% 3 01% 1 00% 3 01% 0 00% 1 0.0%	03 8ep 2018 16 50 (0), 03 8ep 2018 16 50 (0),
B10 Centrally acting antihypertensives B11 ACE or ARB WITH K + 5.5 B12 Spito or splerencome WITH K + spaning drups WITHOUT K + in last 6 months B13 Phosphodiesterase inhibitors AND (Heart failure WITH Systolic <90 OR Grail Nitrate) C01 Aspiritin >160mg C02 Aspiritin AND septir ulter disease WiTHOUTppi	6 0.1 % 3 0.1 % 1 0.0 % 3 0.1 % 0 0.0 % 1 0.0 %	03 Sep 2018 16 50 (0), 03 Sep 2010 16 50 (0), 03 Sep 2010 16 50 (0),
1811 ACE or ARB WITH K * > 5.5 B12 Spire or episemene WiTH K * sparing drups WITHOUT K * in last 6 months B13 Phosphodesterase inhibitors AND (Heart failure WITH Systelic <90 OR Oral Nitrate) C01 Aspirin >16 Dmg C02 Aspirin AND peptic ulcer disease WiTHOUTppi	3 01% 1 00% 1 00% 3 01% 0 00% 1 00%	03 Bep 2018 16 50 (0) 03 Sep 2018 16 50 (0)
B12 Spiro or epierenons WiTH K+ sparing drugs WITHOUT K+ in last 8 months B13 Phosphodiesterate inhibitors AND (Heart failure WITH Systolic <90 OR Grai Nitrate) C01 Aspirin >160mg C02 Aspirin AND peptic ulcer disease WITHOUTppi	1 00% 1 00% 3 01% 0 00% 1 00%	03 Sep 2018 16.50 (A) L 03 Sep 2018 16.50 (A) L 03 Sep 2018 16.50 (A) L 03 Sep 2018 16.50 (A) L
B13 Phosphodiesterase inhibitors AND (Heartfailure WITH Systolic <90 OFI Oral Nitratil) .C01 Aspirin >160mg .C02 Aspirin AND peptic ulcer disease WITHOUTppi	1 0.0% 3 0.1% 0 0.0% 1 0.0%	03 Sep 2018 16 50 (4) 03 Sep 2010 16 50 (4) 03 Sep 2010 16 50 (4)
C01 Aspirin >160mg C02 Aspirin AND peptic ulcer disease WITHOUTppi	3 01% 0 00% 1 00%	03 Sep 2010 16:50 (B). 03 Sep 2018 16:50 (B).
C02 Asptrin AND peptic ulcer disease WITHOUTppi	0 0.0%	63 Sep 2018 16 50 (B) 🙏
	t 0.0 %	
C03 Antipipaled OE anticipant WTM and a 200 OE Meeting disposer		
200 Hiterater on animoadman with star - rep on piceanity disease.	5 01%	03 Bep 2018 16 50 (6) 🙏
C04 Aspirin AND Clopidogrei WITHOUT stent in last 12m or carolid stenosis		03 Bep 2018 16 50 (@) 🙏
CGS Aspirin AND oral anticoagulant in Atrial fibrillation	1 00%	03 Sep 2010 16:50 (R) L
C06 Aspinin AND oral anticoagulant WITHOUT Atrial fibrillation	1 0.0%	03 Sep 2010 16 50 (m) L
CG8 Oral anticoagulant for single DVT >6m ago	3 01%	03 Sep 2018 16 50 (m) 🔍
C89 Onal anticoagulant for single PE + 12m ago	0 0 0 %	03 Sep 2018 16 50 (m) K
C10 NSAID AND oral anticoaguiant	3 01 %	03 84p 2018 16 50 (m) 👢
C11 Antiplatelet AND NSAID without PPI	2.00%	03 Sep 2018 16 50 @
D01 TCA WITH dementia OR plaucoma OR conduction probs OR prostatism	29 0.5%	03 Sep 2018 16:50 (ALL
DQ2 TCA without previous antidecvessant	31 0.5%	03 Sep 2018 16 50 (m) .
D03 Neuroleptics with muscarinic effects WITH prostatism or retention	0.00%	03 Sep 2018 16 50 (m)
D04 SERI AND hyponatraemia in last 6 months	1 0.0 %	03 840 2018 16 50 @
D05 long acting benzo on repeat	19 0 3 %	03 Sec 2018 16:50 (0)
DB6 Antipsychotics other than guel or clozapine WITH Lewy Body or Parkinsons	2 0.0%	03 Sep 2018 16:50 mul
D07 Anticholinergics AND neuroleptics	4 01%	03 Sep 2018 16 50 (BLL
D88 Antimuscamics AND dementa	1 0.0 %	03 Sep 2018 18:50 @
D09 Antipsychotics AND dementia	0 00%	03 Sep 2018 16 50 (@)
D11 Ach infubitors AND HR < 60, Heart block or drugs as listed	6 01%	03 8ep 2018 16 50 (m)
D12 Phenothiagines except prochlor, chlorpro and levomep	0 0.0%	03 Sep 2018 16:50 (@)
D13 Levodopa OR DA AND Essential Tremor WITHOUT PD	0.00%	03 Sep 2018 16:50 (m)
D14 Receal of 1st centration antihistamine	36 0.6 %	03 Sep 2018 16 50 (m) .L
E1 Diposin on repeat >125mcp AND GFR<30	0.00%	03 8ep 2018 16:50 (m) L
E2 Dabisatran AND eGFR-30	0 0.0%	03 Sep 2018 16 50 (m)
E3 Riverpraban OR Apicaban WTH eGFR <15	0 0.0%	03 840 2018 16 50 (0).
E4 NSAD AND eqt+50	0 00%	03 Sep 2018 16 50 (0) 4
E5 Colchicing AND 40FR+10	0.00%	03 Sep 2018 16 50 (m)
E5 Metormin WITH eEFR<30	0 0.0 %	03 Sep 2019 16 50 (mill
F1 Prochiotperazine OR metoclogramide AVD Parkinsons	0 00%	03 54p 2018 16 50 (m)
F2 Treatment dose PPI on repeat	208 3 5 %	03 Sep 2018 16 50 (0)
F2 Considering drugs in patients with constpation coded in tast 2xr	30 0.5%	03 Sep 2018 16:50 (0)
r a consideranty and a matteria wat consequence consequence and an apr	0 0 0 %	03 Sep 2018 16:50 (m)
G1 Orial sterolds, no inhaled sterolds in COPD	5 01 %	03 Sep 2010 16:50 (#)
G3 Antimuscathic inhibites with name plauceme or bladder outflow	0 0.0%	03 Sep 2010 16 50 (0)
A HINGS and PUD (of bled with an even PP)	2 0.0%	03 84p 2018 16:50 (m)
Pri Nanu And Poul Poi bead without Phi	2 0.0%	03 540 2018 16:50 (m)
A statute and a state of the st	55 U.9 % 88 1.5 %	03 Sep 2018 16:50 (m)

STOPP

Or reporting at CCG/federation level

.B01 (Dig NOT attrail fibrillation) NOT LVSD	18 0.0 %	03 Sep 2018 17:07 84
802 Dittagem / Verapamii AND heart taikire	30 0.0%	03 Sep 2018 17:07 18
803 Beta blocker AND (verapamil OR dillizzam)	68 0.3 %	03 Sep 2018 17:07 (61.L
804 beta blocker AND 0-IR<50 Type 2 or complete heart block)	259 0.2 %	03 Sep 2018 17:07 (8)
805 Amiodarone WITHOUT past or present 68 digoxin verapamil or diffiazem	13 0.0%	03 Sep 2018 17:07 10
BD6 (Loop duratic AND hypertension) WITHOUT (Heart failure or antihypertensive medication)	146 0.1 %	03 Sep 2018 17 07 (8)
807 Loop divestic WITHOUT (heart failure, liver failure, neptrotic syndrome OR CKD 4-5)	2054 1.5 W	03 Sep 2018 17:07 ALL
800 Thiacide WITH (Gout or hapokalaemia or haponatraemia or hapercalcaemia)	329 0.2%	03 Sep 2018 17 07 @ L
BD9 Loop duratic WITH hypertension WITH urinary incontinence	441 0.3 %	03 Sep 2019 17:07 @LL
B10 Centrally acting anthropertonsives	324 0.2%	03 Sep 2018 17:07 BLL
B11 ACE or ARB WITH K+ = 5.5	92 0.1 %	03 Sep 2018 17:07
B12 Spino or epierenone WITH K+ sparing drugs WITHOUT K+ in last 6 months	123 0.1%	03 Sep 2018 17:07 (AL
B13 Phosphodiesterase inhibitors AND (Heart failure WITH Bystolic <99 OR Oral Nitrate)	0.00%	03 Sep 2018 17:07 HLL
C01 Aspinin >160mg	20 0.0%	03 Sep 2018 17 07
C02 Aspirin AND peptic ulcer disease WITHOUTpp	20 0.0 %	03 Sep 2018 17:07 18
C03 Antiplatelet OR anticeaguiant WITH syst > 200 OR bleeding disorder	52 0.0 %	03 Sep 2010 17:07 161
C04 Aspirit AND Clopidogrel WITHOUT stent in last 12m or carolid stenosis		
	196 0.1 %	03 Sep 2018 17:07 (8)
CO5 Aspirin AND oral anticoagulart in Abial fibrillation	34 0.0 %	03 Sep 2018 17:07 10
CO6 Aspirin AND oral anticoagulant WITHOUT Atrial fibrillation	25 0.0 %	03 Sep 2018 17:07 👼 🙏
C09 Oral anticoagulant for single DVT >6m ago	118 0.1 %	03 Sep 2018 17:07 🕮 🙏
C09 Oral anticoagutant for single PE > 12m ago	0.0%	03 Sep 2018 17:07 (6)
C10 NSAD AND oral anticoagulant	26 0.0%	03 Sep 2018 17:07 🙉 👢
C11 Antiplatelet AND NSAID without PPI	23 0.0 %	03 Sep 2018 17:07 🙉 👢
D01 TCA WITH dementia OR glaucoma OR conduction prote OR prostatism	495 0.4 %	03 Sep 2018 17:07 (8)
D02 TCA without previous antidepressant	436.0.3 %	03 Sep 2018 17.07 (6)
D03 Neuroleptics with muscarinic effects WITH prostatism or retention	2 0.0 %	03 Sep 2018 17:07 🛍 🙏
.D04 SSRI AND hyponatraemia in last 6 months	20 0.0 %	03 Sep 2018 17:07
D05 long acting benzo en repeat	509 0.4 %	03 Sep 2018 17:07 🙉 🙏
D06 Antipsycholics other than quet or clozapine WTH Lewy Body or Parkinsons	16 0.0 %	03 Sep 2018 17:07 @
D07 Anticholinergics AND neuroleptics	96 0.5 %	03 Sep 2018 17:07 🙉 🙏
D0S Antimuscarinics AND dementia	79 01%	03 Sep 2018 17 07 🙉 🙏
D69 Antipsychotics AND demontia	100 01%	00 Sep 2018 17:07 🙉 🙏
D11 Ach inhibitors AND HR < 50, Heart block or drugs as listed	104 0 1 %	03 Sep 2018 17:07 🙉 🙏
D12 Phenothiazines except prochlor, chlorpro and levomep	15 0.0%	03 Sep 2018 17:07 🙉 🙏
D13 Levodopa OR DA AND Essential Tremor WITHOUT PD	7 0.0%	03 Sep 2018 17:07 @LL
.D14 Repeat of 1st generation antihistamine	773 0.6 %	03 Sep 2018 17:07 @ 1
E1 Digitizin on repeat +125mcg AND GFR +30	0 0.0%	03 Sep 2018 17 07 18
E2 Dabigatran AND eGFR<30	0.00%	03 Sep 2018 17:07 (ELL
E3 Riverovaban OR Apixaban WITH eGFR<15	2 0.0 %	03 Sep 2018 17:07 🙉 👢
E4 NSAD AND eph <50	28.0.0%	03 Sep 2018 17:07 @
E5 Colchicine AND eGFR<10	0.00%	03 Sep 2018 17 07 (ELL
E6 Netformin WITH eGFR<30	8 0.0 %	03 Sep 2018 17:07 HLL
F1 Prochiorperagine OR metoclogramitie AND Parkinsons	0.0%	03 Sep 2018 17:07 🔞 👢
F2 Treatment dose PFI on repeat	6115 4.5 %	03 Sep 2018 17:07 @LL
F3 Constipating drugs in patients with constipation coded in last 2yr	495 0.4 %	03 Sep 2018 17:07
01 Theophyline monotherapy	1 0.0 %	03 Sep 2018 17:07 0
62 Oral steroids, no inhaled steroids in COPD	40.00%	03 Sep 2018 17:07
G3 Antimuscarinic inhalers with narrow glaucoma or bladder outflow	20 0.0 %	03 Sep 2010 17:07 (0)
H1 NSAID And PUD / Gi bleed without PPI	5 0.0%	03 Sep 2018 17:07 (8)
HI NAND KIN POD / Di need withour Phi H2 NSAID with heart failure OR hypertension	757 0.6%	
the network and characterized rectification of the second s	101 0.0 %	03 Sep 2018 17:07

Other Polypharmacy Tools

- MHRA alerts available
 - E.g. statin/calcium channel blocker interaction
 - Citalopram and the elderly
- Anticholinergic burden score beta version being tested
- Anticoagulation prescribing safety system beta version being tested

Flags to identify patients who might be frail. Can be set to different thresholds. More sensitive and specific than eFl alone



** ** 🛥 - *	
	Eligible for Frailty Screen (wider
	definition)
	Eligible for a frailty screen (wider definition)
	2

Or reports to use at whole practice level

* Eligible for frailty screen ('severe' eFI 13/36 cutoff) based on eFI alone	20 0.3 %	03 Sep 2018 17:18 ඬ 🗸
* Eligible for frailty screen - wider definition	39 0.7 %	03 Sep 2018 17:15 🖻 🗸
* Frail but frailty not categorised	0 0.0 %	03 Sep 2018 17:18 🙆 🗸
		<u> </u>

Support for diagnosing and categorising frailty


Frailty

	-	onanging the cor	iounation date will alleet all other data entere	a. To avoia ano, cancer ana pre
Home Frai	ilty Diagnosis Resources R	eports		
Diagnos	ing Frailty		Most Recent Frailty Code	
•			Frailty Screening	
ests are no	atients the diagnosis is very clea t needed. For others use the PR rd Up and Go Test			
Timed up	of frailty should be considered it and go test result if >10s OR core is >=3	the		
hen walking Clinicial jud	nvolves rising from a chair, walki g back to the chair and sitting do gement must be applied e.g. wh e to isolated knee arthritis.	vn		
Launch Pr	risma Calculator			
med up and g	ao mobilit			
New Dia	anosis			
	ox below to categorise the severi	y of frailty and add th	e	
franty code	to the patient's record.			
犬 Cate	gorising Frailty Severity			
Click here i	f the patient is clearly not frail	웃 Apply Not frail		
Categori	ising Frailty Severity			
The GMS	contract requires primary care to	record frailty severity	2	
		이야지 않는 것이 있는 것이 없는 것이 없 않이 않이 않이 않은 것이 없는 것이 없 않이		
Do not use	e the eFI to categorise fraity sevi	anty.		
	he GMS contract only requires fa m a fraity assessment.	Is assessment and n	nedication review in those categorised as 'se	verely' frail, all frail patients will
Streeting	in a namy assessment.			
Frailty Seventy				
Mild	These people often have more	evident slowing, and	need help in high order IADLs (finances, tra	sportation, heavy housework,
has desired			airs shopping and walking outside alone, me	
Moderate			heeping house. Inside, they often have proble minimal assistance (cuing, standby) with dre	
Severe		endent for personal c	are, from whatever cause (physical or cogniti	

Frailty

Dashboard/overview for complex patients:

Integration of similar pathways e.g. dementia, frailty, palliative care, housebound, care homes.



Frailty


Key frailty assessments

Home Fra	ailty	Diagnosis	Resou	rces I	Reports				
					07 Jun 3		Low risk of falls (XaObN)		*
Falls					Most Re	cent F	alls Referral		
									-
				_			y assessment		*
嵀 Dementia	a DES I	DCS		•	12 Mar	2018	Initial memory assessment (Xaah)	0	
									-
💊 Run STO	OPP Pro	otocol		▶ 🔳			tion Review	ſ	, î
💊 Show S	TOPP F	Full Details			08 Aug 06 Aug		Medication review (8B314) Medication review done (XaF8d)	5	
edication re	eview o	done 📃 🖌		' <u>L</u>	UU Aug	2010	Medication review done (Aarod)		-
Calculate	e MUS'	г		1234 567	Malnutr	rition ur	niversal screening tool 2	26 Jun 2018	*
									-
							iagnosis and Screening		· 📩
🏹 Launch I	Depres	ssion screeni	in		08 Oct		Reactive depression (XE1YC)	ြို့ စာ	
					18 Dec			🔮 😨	
				Ľ	12 Mar	2018	Depression screening using que	stions (XaLlc) 🔍 🔍	
				Ļ	Notes		negative		-
犬 Barthel	DCS				– No pei	rforma	nce status recorded		- ^ +
					- Lates	t Conti	nence Information		-
				-	-	n 2018			
									Ŧ

Frailty

 IT support for practices who have batch added frailty diagnoses based on eFI (leads to significant over-diagnosis and overclassification of frailty. E.g. how to batch-undo


RAIDR – Risk Stratification



Population Segmentation

Partnership Name O Organisation Na... O 8 th East & Cill

80



		Mostly healthy elderly (>=75) p	eople - Unpla	anned		
Spinit			Spel 1	10		
Sin.	11X	Other problems of the respiratory system	419	21%	£1,399	209
2	17%	Other problems of the genito unnary system	163	8%	6569	89
3	1000	Other problems of circulation	153	B%	6519	. 89
4	16X	Problems due to Trauma & Injuries	153	6%	£508	7
5	11A	Obstructive Airways Disease	90	4%	E261	45
Other	17.000	Other	1,088	63%	£3,622	535
Total		Total	2,035	100%	£6,869	100%

Spell		Programme Budgeting Classification	Spel	\$	Tariff (£,000s)		
Rank	Code	Description	#	%	#	%	
1	07A	Chronic Pain	260	12%	£195	59	
2	11X	Other problems of the respiratory system	184	9%	£394	509	
3	104	Corohary Heart Disease	165	B%	E427	109	
4	11A	Obstructive Airways Disease	153	7%	£236	- 679	
5	1000	Other problems of circulation	134	6%	.E442	519	
Other	1000	Other	1,200	67%	62,443	58%	
Total		Total	2,096	100%	£4,136	100%	

Spell		Programme Budgeting Classification	Spei	5	Tariff (£,000s)		
Rank	Code	Description	#	%		*	
1	18X	Maternity & Reproductive Health	2,445	22%	£2,819	50%	
2	U7A	Chronic Pain	1.222	11%	E864	59	
3	11X	Other problems of the respiratory system	696	0%	£1,181	. 79	
4	16X	Problems due to Trauma & Injuries	612	6%	£1,824	. 99	
5	07X	Other neurological problems	462	4%	6583	- 39	
Other-	1000	Other	5,672	51%	£10,294	599	
Total		Total	11,089	100%	£17.375	100%	

Durham, Darlington, Tees, Hambleton, Richmondshire and Whitby (DDTHRW)


in	٢	Ø	Ń	68	80	ø	9	4
n	End Of Life	Dementia	Frail/Elderly	Learning Disability	Cancer	Long-Term Condition	Mental Health	Chilli Young
	8,266	11,667	24,699	5.800	32,153	363,054	161,111	268
	11,447	17,950	38.092	6,618	37,414	393,159	156,587	295

Heart Disease

I- CARE: Assess

- I-CARE toolkit
- NEWS monitoring in Care Homes


www.frailtyicare.org.uk



I- CARE: Respond

Timely access to services/care:

- Fight deck
- The RAIDR-UEC App
- Health Call
- Great North Care Record
- Clinical Digital Resource Collaborative
- EoL portal: Black pear, ?Expand MIG to include access to Special Patient Notes (End of Life, Advanced Care Planning, DNACPR, PPC, PPD, ADRT)



Monitoring of NEWS via Care Homes

Digital NEWS tablet is at the heart of *Better Health* and Care for care home residents in Sunderland

NHS Sunderland Clinical Commissioning Group



Why are we introducing technology into care homes?


- · Complex healthcare needs, multiple long term conditions
- Skills within residential care homes not necessarily sufficient
- Communication challenges between providers
- Residents currently do not have equitable access to healthcare which can lead to hospital admissions
- The need to improve early detection of acute illness in residents
- Provides care closer to home to improve patient experience

Outcomes

- Reduction in 111 and 999 calls
- Reduction in A&E visits and emergency admissions
- Sharing of clinical information across all providers
- Promotes collaborative working with providers
- Improved safety and quality of information on handover

Improved early detection of acutely unwell residents

Who has been involved?



Join our journey ...

Flightdeck

- Web based
- NEAS Hosted North East hospital focussed
- Mix of submissions
 - Automated / Manual


Flight Deck Dashboard

Live Hospital Situation Report

tennes	*	× 4	60. 10	ED.	E	Ster -	10-10-10-10-10-10-10-10-10-10-10-10-10-1	ie ja	0	Part I	80- Î.	41. 1	2	en en	the state	r ji
NSECH	1	1	5	4	80	1	11	5	6	8	2	2	0		in the	
RVI	1	4	34	22	122	4	0	18	9	2	2	3	1	2	2	PAEDS DIVERT SOUTH OF T
QEH	1	1	13	0	102	÷	÷	i.	÷.	÷.	w.	5	÷	Ξ.	2	
STDH	÷	÷	÷	÷	~	÷	÷	÷	5	÷	÷	÷	÷	÷	1	-
SRH	2	4	31	19	120	4	20	4	16	27	0	1	0	27	1	
UHND	1	2	10	ú	93	2	•	*	5		÷	÷	-	÷	Q	
DMH	ļ.	Q	10	8	<u>31</u>	8	6	9	0	3	0	0	0	0	2	
NTUH	2	3	a.	ú	92	Ö,	6	5	6	5	ĩ	2	0	0	ĩ	
JCUH	1	<u>0</u>	11	0	2	2	6	2	5	15	2	2	0	0	1	Not inclusive of YAS or A Ambulance
<																>

Join our journey...

App – pressure map



Join our journey...

Easy to use digital health tools. Healthcare at your finger tips

HealthCall

Health Call

Horsy About Ourproducts For Palantis Resources Digital-basilithing Darlactus

County Durham and Darlington

NHS

South Tees Hospitals

North Tees and Hartlepool

Health Call is the largest deployment of digital care technologies in England



NH5 Foundation Tries

The Newcastle Upon NHS

Tyne Hospitals

NHS Foundation Trust

Gateshead Health

inhealthcare



MIG deployment.

Collaboratively delivered across

- 12 Trusts
- 352 General Practices (100%)
- 3.2 million citizens

How will it affect me as a PATIENT?

Your Great North Care Record provides access for health professionals to view your electronic medical records. Can I see the health information held about me?

How will it affect me as a HEALTH

PROFESSIONAL?

CARE

Read More

Clinical Digital Resource Collaborative


Standardising GP practice resources...

- Creates regional EMIS & TPP resources
- Delivered regionally to Standardise:
 - Coded information
 - Ways of working

- Quality
- Reducing variation


Evaluate

- RAIDR Population Health Management Dashboard:
 - Capture baselines and monitor impact
 - Present and monitor frailty outcome metrics



Making it happen


- SharePoint:
 - Enabling collaborative working
 - Many Communities of Practice



Your help!

Transforming care...through technology

"not doing the same thing better, but doing better things"




Information, sharing, empowering...enabling

Transformation requires;

People Process Technology


"not doing the same thing better, but doing better things".

The joining up of health and care data will benefit:





But we need to start somewhere!



and therefore.....

From



То



With




Join our journey...

SystmOne & EMIS integration-Implementing the SLIP programme

- Full GP records viewable from either system
- Bidirectional e.g.
 - Community
 Primary care
- Potential to implement from July
- ISG between Primary care and partners

Our vision: Create a consent-rich research environment





MIG – Sharing patient records

- 100% MIG participation signed data sharing agreements
- Actual MIG activation level is currently 93% and technical work will be done with the now participating practices in South Tees and Newcastle Gateshead to increase this.
- MIG Utilisation by Receiving Orgs July: Successful Access 39,702 (92%) Errors 3,515 (8%)

